Skip to main content

The LEO Foundation

Established in 1984, the Foundation is the controlling owner of LEO Pharma and its main objective is to ensure the company's long-term development and success as a global leader in dermatology, delivering outstanding results.

Until 2021, the Foundation was the sole owner of LEO Pharma. In 2021, the Foundation welcomed Nordic Capital as a minority shareholder and partner to the Foundation, who remains the company’s long-term controlling owner. The partnership with Nordic Capital will further support LEO Pharma’s development and strengthen its position in medical dermatology.

Learn more about the LEO Foundation >

Key LEO milestones:

First Danish pharmacist, a LEO founder Second Danish pharmacist, a LEO founder 1908
LEO Pharma founded by two Danish pharmacists
  1910
3 employees
  1912
First product, Albyl, is marketed
  1926
80 employees
  1940
Heparin LEO® is launched
Leopenicillin 1945
LEO® Penicillin is marketed
  1958
Rontul® and Centyl® are marketed
  1958-1967
LEO expands to France, Holland, Ireland, the UK, Norway, Sweden and Belgium
  1962
Fucidin® is launched
  1978
One-Alpha® is launched
  1983
The LEO Foundation is established
  1984
LEO Canada opens
  1991
Dovonex® and innohep® are launched
  1994
3000 employees worldwide
Daivobet 2001
Dovobet® is launched
Expansion China 2008
100-year anniversary
Expansion to China
LEO 'Going for Gold' strategy announced
  2010
Operations in Brazil, Japan and Mexico initiated
  2012
Picato® is launched

 

View the full LEO Pharma timeline >